ABOUT US

Company Profile

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. We are focused on addressing unmet needs in the field of cancer with our current efforts directed towards the development of hypoxia-activated prodrugs that target treatment-resistant cancer cells.

Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University.

Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland.

To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.